Immunosuppression clinical trials at UC Cancer

• Intra-lesional Nivolumab Therapy for Limited Cutaneous Kaposi Sarcoma

  open to eligible people ages 18 years and up

  There is no clear treatment for patients with limited cutaneous Kaposi sarcoma (KS). Radiation and injection of vinblastine both have side effects that may not be acceptable. Nivolumab has been used to treat more extensive KS when given intravenously. This is, to the investigators' knowledge, the first trial to see if nivolumab can be used as treatment in the form of an injection into KS lesion.

  at UCSF

Last updated: June 12, 2020